On March 29, the general office of the State Council issued the “14th five year plan” for the development of traditional Chinese medicine (hereinafter referred to as the “plan”), which defined the development objectives, main tasks and key measures for the development of traditional Chinese medicine during the “14th five year plan”.
How important is this plan?
According to the reporter, this is the first Five-Year Plan for traditional Chinese Medicine issued in the name of the general office of the State Council.
The plan comprehensively considers the key areas of TCM development such as medical treatment, education, scientific research, industry, culture and international cooperation, puts forward 10 key tasks, and sets up 15 specific development indicators and 11 work columns.
relevant experts from the State Administration of traditional Chinese medicine pointed out that the implementation of the objectives, indicators, key tasks and major policies and measures of the plan will promote the development of traditional Chinese medicine industry into a new stage, make the achievements of traditional Chinese medicine development better benefit the broad masses, and provide strong support for comprehensively promoting the construction of a healthy China and better ensuring people’s health
New era, new goal, clear at a glance!
In the view of insiders, the setting of development indicators more reflects the high-quality development requirements of traditional Chinese medicine in the new era.
How can the development of traditional Chinese medicine reach the standard in the 14th five year plan? We should also rely on the “ten key tasks”.
the plan has deployed ten key tasks, including building a high-quality and efficient traditional Chinese medicine service system, improving the health service capacity of traditional Chinese medicine, building a team of high-quality traditional Chinese medicine talents, building a high-level traditional Chinese Medicine Inheritance and protection and scientific and technological innovation system, promoting the high-quality development of traditional Chinese medicine industry, developing traditional Chinese medicine health service industry, promoting the prosperity and development of traditional Chinese medicine culture, and accelerating the open development of traditional Chinese medicine, We deepened the reform in the field of traditional Chinese medicine and strengthened the support and guarantee for the development of traditional Chinese medicine, and arranged 44 major projects in 11 categories
The reporter of Shanghai Securities News immediately interviewed experts in the traditional Chinese medicine industry and heads of relevant listed companies to interpret the highlights of the plan in detail.
improve the level of integrated traditional Chinese and Western medicine, promote the rational use of traditional Chinese medicine — usher in new opportunities for the development of Chinese patent medicine
The plan proposes to improve the level of integrated traditional Chinese and Western medicine. Promote the coordinated development of traditional Chinese and Western medicine in general hospitals. Build a number of “flagship” hospitals and “flagship” departments of traditional Chinese and Western medicine, and carry out joint research on major and difficult diseases, infectious diseases, chronic diseases and other traditional Chinese and Western medicine.
Zhejiang Conba Pharmaceutical Co.Ltd(600572) Chairman Hu Jiqiang told the reporter of Shanghai Securities News that Chinese patent medicine played a special role in the prevention and treatment of covid-19 pneumonia. The plan specifies the construction of “flagship” hospitals and “flagship” departments, which will help to expand the utilization rate of Chinese patent medicine in hospitals in the future. At present, the utilization rate of Chinese patent medicine in comprehensive medical institutions is still relatively low. If this task is implemented in place, it will have a positive impact on the development of Chinese patent medicine
Jiangsu Kanion Pharmaceutical Co.Ltd(600557) chairman Xiao Wei felt the development opportunity of proprietary Chinese medicine from the detail of “promoting the rational use of traditional Chinese medicine”. Xiao Wei expressed his belief that under the guidance of the plan, clinical institutions at all levels can fully introduce and use Chinese patent medicines, and “make full use of the basic varieties of Chinese patent medicines and medical insurance varieties”. Especially for the innovative drugs of Chinese patent medicine, these varieties have a clear range of disease treatment through clinical evidence-based medicine test evidence, have established the whole process quality control system and intelligent manufacturing technology system, and have been verified by evidence-based medicine research after listing, which further ensures the safety, effectiveness, stable and uniform quality of drugs, and is bound to improve the ability of disease diagnosis and treatment and curative effect for clinic, Truly ensure the accessibility of patients to innovative traditional Chinese medicine.
Similarly, Chongqing Taiji Industry (Group) Co.Ltd(600129) general manager Yu Min sees in the plan that the TCM diagnosis and treatment service based on Chinese patent medicine will usher in new market development space. “The linkage mechanism between specific development indicators and hospital performance appraisal will help promote the comprehensive hospitals to truly achieve the coordinated development of traditional Chinese and Western medicine and identify with traditional Chinese medicine in essence. This measure will take a solid step in promoting traditional Chinese medicine diagnosis and treatment services.” Yu Min told reporters.
promote the high-quality development of traditional Chinese medicine industry – traditional Chinese medicine and traditional Chinese medicine drinks will be favored
In terms of promoting the high-quality development of traditional Chinese medicine industry, the plan proposes to strengthen the production and management of genuine medicinal materials. Formulate and release the national catalogue of genuine medicinal materials and build a breeding system of improved varieties of traditional Chinese medicine strengthen the construction of breeding bases and production bases for improved varieties of genuine medicinal materials, and encourage the use of mountains and woodlands to promote the ecological planting of traditional Chinese Medicine . Improve the development level of traditional Chinese medicine industry, study and promote the construction of information traceability system of traditional Chinese medicine and traditional Chinese medicine pieces.
Experts in the traditional Chinese medicine industry pointed out that the focus of the high-quality development of the traditional Chinese medicine industry mentioned in the plan is to emphasize “drug quality”, rather than the high-quality development of the traditional Chinese medicine industry market, so the development and quality assurance of traditional Chinese medicine are the focus of this time.
Diao Guangjun, general manager of Harbin Pharmaceutical Group traditional Chinese Medicine Co., Ltd. told the reporter of Shanghai Securities News that in recent years, there has been a trend of “bad money expelling good money” in the field of traditional Chinese medicine, and the plan emphasizes the protection and utilization of traditional Chinese medicine resources and requires strengthening the production management of genuine traditional Chinese medicine, which is a great benefit to the leading enterprises and large enterprises in the traditional Chinese medicine industry.
“Harbin Pharmaceutical Group has not only a 200 year old world hall, but also the second traditional Chinese medicine factory of modern pharmaceutical industry. The industrial chain is sound. In the future, Harbin Pharmaceutical Group traditional Chinese Medicine Co., Ltd. will further promote the large variety strategy and play its due role of basic treatment in medical institutions with drugs with definite clinical efficacy.” Diao Guangjun said that in the field of medicinal materials, Harbin Pharmaceutical traditional Chinese medicine, as a leading enterprise in Heilongjiang, has the obligation to make good use of the advantages of Heilongjiang Province with large resources of traditional Chinese medicine and focus on launching genuine medicinal materials such as longjiuwei, so that the whole province and even the whole country can really use good genuine medicinal materials.
as the leader of traditional Chinese medicine, Yunnan Baiyao Group Co.Ltd(000538) has complete reserves and management of traditional Chinese Medicine . The relevant person in charge of the company said that at present, the company has established the traditional Chinese medicine resources division, which has two functional orientations: first, to meet the demand for traditional Chinese medicine raw materials for the production of drugs and health products; Second, carry out business activities such as processing trade of medicinal materials. The two businesses involve more than 300 varieties of conventional Chinese herbal medicines. The company divides these varieties into strategic varieties, core key varieties and conventional varieties, and implements classified management. Among them, strategic varieties include Paris polyphylla, Panax notoginseng, industrial marijuana and other major varieties; The core key varieties are mainly the large varieties of genuine and advantageous medicinal resources in Yunnan.
In addition, in the traceability management of medicinal materials, Yunnan Baiyao Group Co.Ltd(000538) focuses on the two categories of strategic medicinal materials and core varieties, and the management work is being carried out in an orderly manner. Yunnan Province is currently experimenting with the “fresh processing” of traditional Chinese medicine, which was piloted earlier in the national traditional Chinese medicine industry. Yunnan Baiyao Group Co.Ltd(000538) obtained the pilot of two varieties. At present, the fresh processing systems of these two varieties have been established.
develop minority medicine — the value of minority medicine appears
The plan proposes to develop minority medicine. Strengthen the research on the prevention and treatment of major diseases and dominant diseases by ethnic minority medicine, and effectively inherit the characteristic diagnosis and treatment technologies and methods. Strengthen the inheritance and protection of ethnic minority medicine, continue to carry out the rescue and sorting of ethnic minority medicine literature, and promote theoretical and technological innovation.
The relevant person in charge of the State Administration of traditional Chinese Medicine analyzed that to develop minority medicine, we should first increase policy support for minority medicine. Speed up the implementation of the law on traditional Chinese medicine and the opinions in ethnic minority areas. In the revision of relevant laws and regulations, fully consider the characteristics and development law of minority medicine support the inclusion of qualified minority medicine varieties into the list of Medicare drugs according to regulations, and include qualified minority medical diagnosis and treatment projects into the payment scope of basic medical insurance fund according to regulations , encourage ethnic minority areas to provide and use appropriate minority medical services, and improve the price management of minority medical services.
build a high-level traditional Chinese Medicine Inheritance and protection and scientific and technological innovation system – strengthen support for traditional Chinese medicine innovation
The plan proposes to strengthen tackling key problems in key areas. Increase support for scientific and technological innovation of traditional Chinese medicine in national scientific and technological plans such as scientific and technological innovation 2030 – major projects and key R & D plans. Deepen the research on major scientific issues such as the original theory of traditional Chinese medicine and the action mechanism of traditional Chinese medicine. We will carry out diagnosis, treatment and clinical research on the prevention and treatment of major, refractory, rare diseases and emerging infectious diseases with traditional Chinese medicine.
Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) general manager Chen Hai told reporters that the highlight of the plan is to further establish and improve the evaluation index system and institutional mechanism suitable for the inheritance, innovation and development of traditional Chinese medicine from the national strategic level Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) started with traditional Chinese medicine. At present, the industrial layout of traditional Chinese medicine dominated by traditional Chinese medicine and the coordinated development of biological and chemical drugs has been formed. In the next step, taking the introduction of the plan as an opportunity and the company’s traditional Chinese Medicine Research Institute as the base, it will further strengthen the innovation of traditional Chinese medicine, accelerate the listing speed of secondary innovative new drugs of traditional Chinese medicine, take the subsidiary Bozhou herbal medicine trading center as the main body, upgrade the industrial layout of traditional Chinese medicine supply chain, and from the perspective of system construction and capital investment, Fully realize the high-quality development of the company’s traditional Chinese medicine industry, and take the company’s brand construction as the carrier to contribute to the prosperity of Chinese traditional Chinese medicine culture.
accelerating the opening and development of traditional Chinese medicine — adding “new impetus” to the internationalization of traditional Chinese Medicine
The plan proposes that one belt, one road, and high quality should be integrated into the “one belt” approach to promote the quality of Chinese medicine overseas centers and the establishment of international cooperation bases for Chinese medicine.
Jiuzhitang Co.Ltd(000989) Dong Jun Han one pointed out that one belt, one road construction, is conducive to the internationalization of Chinese medicine. In recent years, Jiuzhitang Co.Ltd(000989) is also actively promoting the internationalization of traditional Chinese medicine. Last year, the company cooperated with Guangdong Macao traditional Chinese medicine science and Technology Industrial Park to promote product export. Seven main products obtained registration approval in Brazil and continued the exploration of internationalization of traditional Chinese medicine.
“On the whole, Jiuzhitang Co.Ltd(000989) ‘s products have always taken high quality as the first priority in terms of drug purchase, processing methods and pharmaceutical technology. From the perspective of enterprises, we will continue to strive to make drugs with high quality and high price and adhere to the high-quality development of traditional Chinese medicine.” Han Chenxiao said.
